OTCMKTS:HEMAHemaCare Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding HemaCare Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $25.31 0.00 (0.00 %) (As of 01/3/2020) Add Compare Share Today's Range$25.31Now: $25.31▼$25.3150-Day Range$25.31MA: $25.31▼$25.3152-Week Range$8.62Now: $25.31▼$26.23Volume5,500 shsAverage Volume59,577 shsMarket Capitalization$346.49 millionP/E RatioN/ADividend YieldN/ABeta1.47 ProfileAnalyst RatingsAdvanced ChartCompetitorsFinancialsHeadlinesSEC FilingsSocial Media HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for HemaCare. Previous Next 2.4 Community Rank Outperform VotesHemaCare has received 25 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHemaCare has received 27 “underperform” votes. (Add your “underperform” vote.)Community SentimentHemaCare has received 51.92% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about HemaCare and other stocks. Vote “Outperform” if you believe HEMA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HEMA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHemaCare does not currently pay a dividend.Dividend GrowthHemaCare does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HemaCare insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 26.20% of the stock of HemaCare is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HEMA Previous Symbol CUSIP423498104 CIK801748 Webwww.hemagen.com Phone818-226-1968Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares13,690,000Market Cap$346.49 million Next Earnings DateN/A OptionableNot Optionable $25.31 0.00 (0.00 %) (As of 01/3/2020) 30 days | 90 days | 365 days | Advanced Chart Receive HEMA News and Ratings via Email Sign-up to receive the latest news and ratings for HEMA and its competitors with MarketBeat's FREE daily newsletter. HemaCare (OTCMKTS:HEMA) Frequently Asked Questions How has HemaCare's stock been impacted by COVID-19 (Coronavirus)? HemaCare's stock was trading at $25.31 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HEMA stock has increased by 0.0% and is now trading at $25.31. View which stocks have been most impacted by Coronavirus. Has HemaCare been receiving favorable news coverage? Press coverage about HEMA stock has been trending negative on Saturday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HemaCare earned a news impact score of -2.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about HemaCare. Who are some of HemaCare's key competitors? Some companies that are related to HemaCare include EHang (OTRK), Tivity Health (TVTY), Catasys (CATS), American Renal Associates (ARA), Emmaus Life Sciences (EMMA), CRYO-CELL International (CCEL), Baudax Bio (BXRX), Pacific Health Care Organization (PFHOD), Caladrius Biosciences (CLBS), Pacific Health Care Organization (PFHO), BioRestorative Therapies (BRTX) and American Caresource (GNOW). View all competitors. What other stocks do shareholders of HemaCare own? Based on aggregate information from My MarketBeat watchlists, some companies that other HemaCare investors own include First Majestic Silver (AG), Discovery Communications (DISCA), Cognizant Technology Solutions (CTSH), Canadian Solar (CSIQ), Conduent (CNDT), Cabot Microelectronics (CCMP), Athenex (ATNX), Apollo Commercial Real Est. Finance (ARI), Artisan Partners Asset Management (APAM) and Ambarella (AMBA). Who are HemaCare's key executives? HemaCare's management team includes the following people: Mr. Peter C. van der Wal, Pres, CEO & Director (Age 62)Ms. Rochelle J. Martel M.B.A., CPA, Chief Financial OfficerMs. Maria Pia Muniz, Sr. VP of OperationsMr. Lou Juliano, Sr. VP of Global Sales & Bus. Devel.Dr. Dominic Clarke, Global Head of Cell Therapy What is HemaCare's stock symbol? HemaCare trades on the OTCMKTS under the ticker symbol "HEMA." How do I buy shares of HemaCare? Shares of HEMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is HemaCare's stock price today? One share of HEMA stock can currently be purchased for approximately $25.31. How big of a company is HemaCare? HemaCare has a market capitalization of $346.49 million. What is HemaCare's official website? The official website for HemaCare is www.hemagen.com. How can I contact HemaCare? HemaCare's mailing address is 15350 SHERMAN WAY SUITE 350, VAN NUYS CA, 91406. The company can be reached via phone at 818-226-1968 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
